🚨 The ATTRACTION trial at #ESOC2026 shows adjunct tirofiban after successful thrombectomy improves outcomes in acute ischaemic stroke.
✅ 49.3% vs 43.3% functional independence (90 days)
📈 Significant benefit (RR 1.15; p=0.01)
🧠 No increase in sICH or mortality
@ESOstroke
#MondayTip#ISC2026
🌎ISC delivered fewer “home runs” and more hard truths: what works, what doesn’t, and where selection matters most in stroke care
From extended-window thrombolysis to FXIa inhibition, #ISC26 highlights where stroke care is truly moving — and where it isn’t.
Have you ever struggled with finding the true lumen of the dissected carotid or vertebral artery? 🧐
💡Check our bail out technique that is easy to use and may save your day / patients’ brain 🧠 https://t.co/P30JCFBPMF
Interesting findings of the COBRA trial showing lower bleeding risk with apixaban compared to Rivaroxaban in VTE. This may partially explain some of the discrepancy in findings between the SECRET trial (using Rivaroxaban) & ACTION-CVT in patients with CVT (2/3rd used apixaban).
These guidelines are the result of an impressive collaborative effort involving module working group chairs, members and methodologists.
As Co-chair of the ESO Guideline Board, it has been a privilege to support this process and witness the dedication of everyone involved.
⬇️
Here's a review on some of the inherited thrombophilias that are frequently ordered as part of the hypercoagulability workup in arterial ischemic stroke. Read on to see which are recommended to be sent in the acute stroke workup, and which should not be ordered. #stroke#MedEd #neurotwitter #medtwitter #medstudenttwitter #neurology
The TEMPO-2 trial led to controversy regarding the utility of thrombolysis in patients with NIHSS 0-5 who have an intracranial vessel occlusion. Below is a thread dissecting the trial and available data on minor stroke as well as my interpretation of the trial and practice. 🧵
Microvascular Perfusion Abnormalities After Successful Endovascular Treatment in Acute Ischemic Stroke — An Indicator of Functional Outcomes
In this #BloggingStroke post, @chris7ianb discusses #Stroke article by @adnan_mujanovic et al. #AHAJournals
https://t.co/OBp7MVbUIs
Early reports suggest Middle Meningeal Artery Embolization #MMAe for medically refractory #headaches and #migraines has beneficial effects for symptomatic control.💥
Lidocaine injection into STA to meningeal artery anastomotic branches provides on the table confirmation of improvement followed by Onyx Embolization for lasting relief.
#endovascular #MMAe #neurosurgery #headache
#ESOC2024
📢NEWS Basilar ESO guideline
👉IVT up to 24 hs
👉EVT up to 24 hs for NIHSS ≥10
👉EVT/IVT if NOT extensive y/or brainstem isquemia
👉Aspiration better than stent retriever
👉Rescue PTA/stenting if failed EVT
👉Add APT if complicated EVT an not IVT